Organisation paid for research Program year 2025 Source: CMS Open Payments

Retina Northwest PC

Neither a doctor nor a teaching hospital

Research payments

$4,302,339

353 payments

Through program year 2025, Retina Northwest PC is reported as receiving $4,302,339 in research payments, across 353 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$386,708	67
2024	Research	$821,624	40
2023	Research	$499,547	51
2022	Research	$630,141	35
2021	Research	$634,597	36
2020	Research	$766,157	42
2019	Research	$563,565	82

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $2,962,259 222 payments
Novartis Pharmaceuticals Corporation $819,183 11 payments
Bayer HealthCare Pharmaceuticals Inc. $336,804 46 payments
Regeneron Pharmaceuticals, Inc. $112,492 23 payments
Apellis Pharmaceuticals, Inc. $38,001 13 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $18,071 11 payments
Astellas Pharma Global Development $5,980 1 payment
Aerie Pharmaceuticals, Inc. $3,500 1 payment
Boehringer Ingelheim International GmbH $3,390 24 payments
AbbVie, Inc. $2,659 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-Of-Concept Study to Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related MacUlar Degeneration $714,103 3 payments
Va2 Phiii $623,564 16 payments
Port Delivery System of Ranibizumab Extension Study $579,762 32 payments
Open Label Extension Study to Evaluate the Long Term Safety of Faricimab in Patients With Namd $337,208 19 payments
Port Delivery System for Ranibizumab $330,216 19 payments
Va2 Phiii Yosemite $288,399 14 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $235,602 30 payments
Port Delivery System of Ranizibumab Extension Study $215,826 11 payments
BAY865321, HD 8mg, AMD - Ph 3 $205,777 14 payments
Lucentis Fsv4 Lad Amd Ladder $158,505 60 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.